Bluebird Bio
About
Genetix Biotherapeutics, formerly Bluebird Bio, develops and commercializes one-time administered genetic therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. These therapies treat the underlying cause of rare genetic diseases by modifying a patient's own blood stem cells to restore gene function. The company is focused on commercial execution, scaling patient access, and improving the treatment experience.
Key facts
At-a-glance profile data
- Website
- genetixbiotx.com
- Headquarters
- Somerville, United States
- Founded
- 1992
- Employees
- 137
- Total funding
- $1.0B (Series D)
- Business model
- B2B
Tech stack
Detected on genetixbiotx.com and in its job posts, last scanned 25 Sept 2026. Run your own scan
- Frontend
- Bootstrap
- Auth
- Okta
- Analytics
- Google Tag Manager
- CDN
- Cloudflare
- Hosting
- Google Cloud
- Email provider
- Microsoft 365, SendGrid
- Cookie consent
- Cookiebot
Add first review
Frequently asked
How much funding has Bluebird Bio raised?
Bluebird Bio has raised a total of $1.0B in funding. The most recent round on record is Series D.
How many employees does Bluebird Bio have?
Bluebird Bio has approximately 137 people on record.